Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma
Launched by CHENGJUN SUI,MD · Nov 30, 2022
Trial Information
Current as of February 05, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Histologically confirmed intrahepatic cholangiocarcinoma They are between 18 and 80 years old Written informed and signed consent form Biopsy sample of the intrahepatic bile duct
- Exclusion Criteria:
- • - Under 18, over 80 Informed consent cannot be given Biopsy samples were not available
Trial Officials
chengjun sui, dr.
Principal Investigator
Deputy director
About Chengjun Sui,Md
Dr. Chengjun Sui, MD, is a dedicated clinical trial sponsor with extensive experience in advancing medical research and development. With a strong focus on innovative therapies and patient-centered approaches, Dr. Sui leads trials that aim to improve healthcare outcomes across various therapeutic areas. His commitment to rigorous scientific standards and ethical practices ensures that all trials are conducted with the utmost integrity, fostering collaboration among multidisciplinary teams and stakeholders. Dr. Sui's expertise and leadership contribute significantly to the progression of clinical research, ultimately aiming to enhance treatment options and improve the lives of patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials